Your browser doesn't support javascript.
loading
Alopecia Areata in Latin America: Where are We and Where are We Going?
Velásquez-Lopera, Margarita M; Hernández, Natalia; Jansen, Angela Marie; García, Angela Londoño; Luna, Paula Carolina; Rico-Restrepo, Mariana; Del Mar Saez-de-Ocariz, María; Tamayo-Buendía, María Margarita; Rivitti-Machado, Maria Cecilia.
Affiliation
  • Velásquez-Lopera MM; Centro de Investigaciones Dermatológicas CIDERM, Sección de Dermatología, Facultad de Medicina, Universidad de Antioquia, Cra. 51D # 62-29, Medellín, Colombia. margarita.velasquez@udea.edu.co.
  • Hernández N; Dermatosoluciones SAS, Bogotá, Colombia.
  • Jansen AM; Americas Health Foundation, Washington, DC, USA.
  • García AL; Dermatology Department, CES University, Medellín, Colombia.
  • Luna PC; Hospital Alemán, Buenos Aires, Argentina.
  • Rico-Restrepo M; Americas Health Foundation, Bogotá, Colombia.
  • Del Mar Saez-de-Ocariz M; Department of Dermatology, National Institute of Pediatrics, Mexico City, Mexico.
  • Tamayo-Buendía MM; Pontificia Universidad Javeriana, Bogotá, Colombia.
  • Rivitti-Machado MC; Departamento de Dermatologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Dermatol Ther (Heidelb) ; 13(1): 95-114, 2023 Jan.
Article in En | MEDLINE | ID: mdl-36527577
ABSTRACT
Alopecia areata (AA) represents an underrecognized burden in Latin America (LA), severely impacting quality of life (QoL). This impact is exacerbated by limited access to specialized dermatologic care and therapies for AA within and among nations. Many of the unmet needs for AA globally also exist in LA. The region has geographic, ethnic, cultural, and economic conditions. With new AA medicines targeting immunologic pathways on the horizon, LA must prepare regarding regulatory issues, reimbursement, awareness, and education to give adequate and timely treatment for patients with AA. To address these issues, the Americas Health Foundation convened a panel of six dermatologists from Argentina, Brazil, Colombia, and Mexico who are experts in AA and its comorbidities for a 3-day virtual meeting to discuss AA diagnosis and treatment in LA and create a manuscript offering recommendations to address discussed barriers. This publication examines unmet AA needs in LA, treatment, and innovative therapies and recommends improving AA care. Access constraints to conventional and novel medicines hinder appropriate treatments for patients. Therapy initiation delays can affect QoL, mental health, and disease progression. People with AA face stigmas, discrimination, and misconceptions owing to a lack of disease awareness. With promising new treatments for AA on the horizon, all stakeholders must coordinate efforts to enhance LA's AA management landscape and improve patient outcomes.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline Aspects: Patient_preference Language: En Journal: Dermatol Ther (Heidelb) Year: 2023 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline Aspects: Patient_preference Language: En Journal: Dermatol Ther (Heidelb) Year: 2023 Document type: Article Affiliation country: